Lv41
480 积分 2023-08-01 加入
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
4小时前
待确认
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
4小时前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
7小时前
已完结
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
8小时前
已完结
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
9小时前
已完结
The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
22天前
已完结
Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial
1个月前
已完结
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients
1个月前
已完结
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
皖公网安备34019202002308
